Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibercept), Stoboclo® and Osenvelt® (denosumab) in the EU marketEuropean Commission approval based on totality of evidence including extensive comparative analytical, pharmacokinetic and clinical dataThe company expands its biosimilar portfolio to 11 in 2025 as planned, further strengthening its commitment to a portfolio of 22 drugs by 2030

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt^® (CT-P42, aflibercept), a biosimilar to Eylea^® to treat multiple retinal disorders, including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO, branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularisation (myopic CNV); and Stoboclo^® and Osenvelt^® (CT-P41, denosumab), biosimilars referencing Prolia^® and Xgeva^® used for all indications of the reference products. The EC approval expands Celltrion’s diverse biosimilars portfolio across multiple therapeutic areas such as skeletal-related disorders and ophthalmology.

“Celltrion is committed to expanding access to high-quality monoclonal antibody treatments for patients across Europe,” said Taehun Ha, Senior Vice President and Head of Europe at Celltrion. “Securing regulatory approval for three biosimilar products on the same day highlights our commitment to providing healthcare professionals with reliable, effective, and accessible treatment options for their patients. With a portfolio of 11 biosimilar brands and a fully integrated approach—from research and development to manufacturing and direct supply—Celltrion is increasing treatment options, improving patient access to biologics, and strengthening its role as a trusted partner for healthcare professionals in Europe, all while supporting the sustainability of healthcare systems.”

Data showed that Eydenzelt^®(40 mg/mL solution for injection in vial and pre-filled syringe), Stoboclo^® (60 mg solution for injection in pre-filled syringe) and Osenvelt^® (120 mg solution for injection in vial) have comparable quality, safety and efficacy when compared to their respective reference products, Eylea^® (aflibercept) and Prolia^® and Xgeva^® (denosumab), respectively. ^1,2,3

“The European Commission approval of Eydenzelt^®, Stoboclo^® and Osenvelt^®are a significant milestone and a welcome addition to our portfolio of medicines to address a significant unmet need in therapeutic areas including skeletal-related disorders and ophthalmology,” said Min Kyoung Jeon, Vice President and Head of Regulatory Affairs Division at Celltrion. “The approval highlights Celltrion’s continuous commitment to expanding the availability, access and uptake of these important treatment options to patients with unmet needs.”

The company’s therapeutics include a total of 11 biosimilar products: 4 immunology products, including Remsima^®/Inflectra^® (US), Remsima^® SC, Yuflyma^®, and SteQeyma^®; 3 oncology products, including Truxima^®, Herzuma^®, and Vegzelma^®; and other therapeutic areas, including Omlyclo^®, Eydenzelt^®, Stoboclo^® and Osenvelt^®.

About CT-P41 Phase III Clinical Trial
The Phase III study randomised 479 patients to receive 60 mg of CT-P41 or reference product every six months (Weeks 0 and 26; treatment period [TP] I). Results of the study showed that CT-P41 had equivalent efficacy and pharmacodynamics to reference denosumab, with similar pharmacokinetic and comparable safety and immunogenicity profiles.³

About CT-P42 Phase III Clinical Trial
In a randomised, double-masked, parallel-group, multi-centre Phase III study of Eydenzelt^® (CT-P42), the efficacy, safety, pharmacokinetics, usability and immunogenicity of Eydenzelt^® was compared to Eylea^® (aflibercept) in patients with diabetic macular edema (DME). Results of the study showed that Eydenzelt^® met the predefined equivalence criteria, and secondary endpoints of efficacy, safety, and immunogenicity also showed trends similar to Eylea^®.^1,2

About Stoboclo^® (CT-P41, biosimilar denosumab)
Stoboclo^® (denosumab), a receptor activator of NF-κb ligand (RANKL) inhibitor, is a treatment developed as a biosimilar to reference product Prolia^® (denosumab). In Europe, Stoboclo^® has been approved to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, and bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.⁴ Stoboclo^® was also filed for regulatory approval with the U.S. Food and Drug Administration (FDA).

About Osenvelt^® (CT-P41, biosimilar denosumab)
Osenvelt^® (denosumab) is a receptor activator of NF-κb ligand (RANKL) inhibitor developed as a biosimilar referencing Xgeva^® (denosumab). Osenvelt^® has been approved in Europe to prevent skeletal-related events in adults with advanced malignancies involving bone, and to treat adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.⁵ Osenvelt^® was also filed for regulatory approval with the U.S. Food and Drug Administration (FDA).

About Eydenzelt^® (CT-P42, biosimilar aflibercept)
Eydenzelt^® (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor referencing Eylea^®. Based on comprehensive data from a Phase III clinical trial confirming therapeutic equivalence to Eylea^®3, Eydenzelt^® is approved to treat neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO, branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularisation (myopic CNV).⁶ Eydenzelt^® was also filed for regulatory approval with the U.S. Food and Drug Administration (FDA).

About Celltrion
Celltrion is a leading biopharmaceutical company that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, haematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook.

FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business, and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares,” “hopes to,” “upcoming,” ”plans to,” “aims to,” “to be launched,” “is preparing,” “once gained,” “could,” “with the aim of,” “may,” “once identified,” “will,” “working towards,” “is due,” “become available,” “has potential to,” the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

Stoboclo^® and Osenvelt^® are registered trademarks of Celltrion Inc.
Prolia^® and Xgeva^® are registered trademarks of Amgen Inc.

Eydenzelt^® is a registered trademark of Celltrion Inc.
Eylea^® is a registered trademark of Bayer AG.

References

_____________________________________
¹ Sebastian Wolf et al., Long-term efficacy and Safety of CT-P42 compared to Reference Aflibercept in Diabetic Macular Edema: 52-Week Results from the Phase 3 CT-P42 3.1. [EURETINA 2024, Abstract #CA24-2257-8397]. Available at: https://abstracts.euretina.org/2024/ca24-2257-8397/r/recxUD7DqYfFfjC7s [Last accessed February 2025].
² Sebastian Wolf et al., Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study. Available at: https://www.sciencedirect.com/science/article/pii/S2468653024003063 [Last accessed February 2025].
³ Reginster JY et al. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. Osteoporos Int. 2024 Nov;35(11):1919-1930. doi: 10.1007/s00198-024-07161-x. Epub 2024 Jul 23. PMID: 39042292; PMCID: PMC11499533. Available at: https://pubmed.ncbi.nlm.nih.gov/39042292/ [Last accessed February 2025].
⁴ European Medicines Agency Summary of Product Characteristics (SmPC), Stoboclo. [Last accessed February 2025].
⁵ European Medicines Agency Summary of Product Characteristics (SmPC), Osenvelt. [Last accessed February 2025].
⁶ European Medicines Agency Summary of Product Characteristics (SmPC), Eydenzelt. [Last accessed February 2025].

View source version on businesswire.com: https://www.businesswire.com/news/home/20250206269326/en/